The government explained that unusual thrombosis, which is recognized to be related to AstraZeneca's COVID-19 vaccination, occurs very rarely.
At a regular briefing, the head of the Corona 19 Vaccination and Response Promotion Director Jeong Eun-kyung said, "The rare thrombosis is very rare, but it can be cured if it is detected and treated early."
"Rare thrombosis occurs in about 1 person per million people," Jeong said. "We will guide the detection of symptoms as early as possible and cooperate with the medical community to promptly treat and respond to the system," he said.
The Vaccination Committee believes that most of the successive cases of'thrombosis' reported in Europe after AstraZeneca vaccination are very rare specific thrombosis with low platelet count and some bleeding.
The European Medicines Agency sees'rare thrombosis' differently from general thrombosis disease, and the promotion team explained that this includes cerebral sinus thrombosis and visceral venous thrombosis, which are caused by platelet reduction.
In Korea, it has been reported that all three had symptoms of blood clots after receiving the AstraZeneca vaccine, but two of them were not recognized for causality with vaccination.
The other case was recognized for causality, but it did not correspond to the case defined by the European Medicines Agency as an adverse event because there was no symptom of platelet reduction.